BPMC - Blueprint Medicines  GAAP EPS of -$2.65 beats by $0.02 revenue of $38.78M beats by $5.26M

• Blueprint Medicines press release ( NASDAQ: BPMC ): Q4 GAAP EPS of -$2.65 beats by $0.02 .
• Revenue of $38.78M (-63.8% Y/Y) beats by $5.26M .
• Revenues were $38.8 million for the fourth quarter of 2022, including $30.1 million of net product revenues from sales of AYVAKIT/AYVAKYT and $8.7 million in collaboration revenues.
• Blueprint Medicines today announced it anticipates approximately $130 million to $140 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023.

For further details see: